Filter posts

Mesothelioma: Once Hopeless Cancer, on the Verge of Promising Advances

Mesothelioma, the word, (pronounced mez-uh-thee-lee-oh-muh) is often much better known than the illness it represents. …

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

To even the most casual observer, 2015 has been a big year in the biotech …

Roll Call: Patient-Centeredness, Comparative Effectiveness, and Value

In Roll Call, Tony Coelho former House Majority Whip, Chairman of the Partnership to Improve …

Wall Street Journal: Patients Deserve Better

In case you missed it, The Wall Street Journal published my Letter to the Editor …

Emerging Themes in Personalized Medicine

The adoption of Personalized Medicine is being driven by the omnipresence of Next-Generation Sequencing (NGS), …

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, …

Biopharma Companies Fight Tropical Diseases to Improve Global Health

Neglected tropical diseases (NTDs) are a group of devastating viral, bacterial, and parasitic diseases that …

Dr. Scott Gottlieb: A Clintonian Misdirection on Drug Prices

Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and …

Discover Trends and Investment Opportunities at the BIO Investor Forum

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event …

Wall Street Journal: The Assault on Drug Innovation

Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s …